首页> 外国专利> QUALITATIVE DIFFERENTIAL INSTANT DIAGNOSTIC TECHNIQUE FOR PAROTID GLAND GROWTHS SHOWN BY PATIENT'S ORAL FLUID BIOMARKERS

QUALITATIVE DIFFERENTIAL INSTANT DIAGNOSTIC TECHNIQUE FOR PAROTID GLAND GROWTHS SHOWN BY PATIENT'S ORAL FLUID BIOMARKERS

机译:患者口腔流体生物标志物显示腮腺生长的定性差速即时诊断技术

摘要

FIELD: medicine.;SUBSTANCE: technique involves performing a patient's oral fluid analysis with the patient's oral fluid sampled prior to or not less than 30 minutes following meals, centrifuging the patient's oral fluid at 3000 rpm for 15 minutes, diluting the oral fluid with physiological solution in a ratio of 1:100 and centrifuging once again at 3000 rpm for 15 minutes, placing the prepared patient's oral fluid material into a tray and performing a standard enzyme immunoassay of monoclonal antibodies; that is followed by the findings analysis; the oral fluid is sampled from the patient for the purpose of qualitative differential instant diagnosis of the parotid gland growths as shown by the oral fluid biomarkers; the biomarker is matrix metal metalloproteinase 8 (MMP 8) to be measured in the patient's oral fluid; the qualitative content of the biomarker MMP 8 of the clinical reference oral fluid biomarker is 23.85-39.65 ng/ml, and if MMP 8 is found in an amount of 611.32-792.00 ng/ml, the parotid gland adenoma is diagnosed, and if MMP 8 is found in an amount of 496.86-570.33 ng/ml, the parotid gland cancer is diagnosed; matrix metalloproteinase 9 (MMP 9) is measured in the patient's oral fluid; the clinical reference oral fluid biomarker makes 108.14-180.47 ng/ml; if MMP9 is found in an amount of 326.43-458.23 ng/ml, the parotid gland adenoma is diagnosed, and if MMP9 making 782.13-906.60 ng/ml enables diagnosing the parotid gland cancer; the derived values of the patient's oral fluid biomarkers are used to predict a therapeutic approach to the patient.;EFFECT: higher accuracy, sensitivity of the differential instant diagnosis, high probability of detection of benign and malignant new growths in the patient's body both at the early stages, and at the later stages, simplified preparation of the patient within the time frame for sampling and storing the diagnostic material.;3 cl, 6 ex
机译:领域:医学;物质:该技术涉及对饭前或饭后30分钟之前采样的患者的口腔液进行患者的口腔液分析,以3000 rpm的速度将患者的口腔液离心15分钟,然后用生理学稀释口腔液溶液以1:100的比例混合,并以3000 rpm的速度再次离心15分钟,将准备好的患者的口腔液放入托盘中,并进行单克隆抗体的标准酶免疫测定。随后进行调查结果分析;从患者身上取样口腔液,以定性,即时诊断腮腺生长,如口腔液生物标志物所示;生物标志物是要在患者口腔液中测量的基质金属金属蛋白酶8(MMP 8);临床参考口服生物标志物的生物标志物MMP 8的定性含量为23.85-39.65 ng / ml,如果发现MMP 8的含量为611.32-792.00 ng / ml,则诊断为腮腺腺瘤,并且如果MMP发现8的量为496.86-570.33 ng / ml,诊断出腮腺癌;在患者的口腔液中测量基质金属蛋白酶9(MMP 9);临床参考口服液生物标志物的浓度为108.14-180.47 ng / ml;如果发现MMP9的量为326.43-458.23 ng / ml,则诊断出腮腺腺瘤,并且如果MMP9的诊断结果为782.13-906.60 ng / ml,则可以诊断腮腺癌;患者口服液体生物标志物的推导值可用于预测对患者的治疗方法。效果:更高的准确性,差异即时诊断的敏感性,在患者体内同时检测到患者体内良性和恶性新生长的可能性很高。早期和后期,简化了在采样和存储诊断材料的时间范围内对患者的准备。; 3 cl,6 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号